Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, ...
MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs
Source: eagletribune.com